OBJECTIVES: Several studies suggested that CD30 expression is a favorable prognostic marker in transformed mycosis fungoides (tMF). However, evidence in this field is still unclear. This systematic review and meta-analysis aimed to evaluate the prognostic significance of CD30 in tMF. METHODS: Electronic databases were searched from their inception to June 2020 for all studies assessing the prognostic value of CD30 in tMF. Pooled hazard ratio (HR) for death was calculated; a P value less than .05 was considered significant. Inconsistency index (I2) was used to assess statistical heterogeneity among studies. RESULTS: Seven studies with 323 patients were included. CD30 expression in tMF was significantly associated with a decreased hazard of death both on univariate (HR, 0.459; 95% confidence interval [CI], 0.319-0.660; P < .001) and multivariate analysis (HR, 0.503; 95% CI, 0.345-0.734; P < .001), and the statistical heterogeneity among studies was null in all analyses (I2 = 0%). CONCLUSIONS: tMF cases with CD30 expression in large cells have a hazard of death two times lower than CD30-negative cases.
Prognostic Significance of CD30 in Transformed Mycosis Fungoides / Travaglino, A.; Russo, D.; Varricchio, S.; Pignatiello, S.; Baldo, A.; Picardi, M.; Pane, F.; Mascolo, M.. - In: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. - ISSN 1943-7722. - 156:3(2021), pp. 350-355. [10.1093/ajcp/aqaa261]
Prognostic Significance of CD30 in Transformed Mycosis Fungoides
Travaglino A.;Russo D.;Varricchio S.;Pignatiello S.;Baldo A.;Picardi M.;Pane F.;Mascolo M.
2021
Abstract
OBJECTIVES: Several studies suggested that CD30 expression is a favorable prognostic marker in transformed mycosis fungoides (tMF). However, evidence in this field is still unclear. This systematic review and meta-analysis aimed to evaluate the prognostic significance of CD30 in tMF. METHODS: Electronic databases were searched from their inception to June 2020 for all studies assessing the prognostic value of CD30 in tMF. Pooled hazard ratio (HR) for death was calculated; a P value less than .05 was considered significant. Inconsistency index (I2) was used to assess statistical heterogeneity among studies. RESULTS: Seven studies with 323 patients were included. CD30 expression in tMF was significantly associated with a decreased hazard of death both on univariate (HR, 0.459; 95% confidence interval [CI], 0.319-0.660; P < .001) and multivariate analysis (HR, 0.503; 95% CI, 0.345-0.734; P < .001), and the statistical heterogeneity among studies was null in all analyses (I2 = 0%). CONCLUSIONS: tMF cases with CD30 expression in large cells have a hazard of death two times lower than CD30-negative cases.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
